Last Updated: November 8, 2026

Details for Patent: 12,734,126

« Back to Dashboard


Which drugs does patent 12,734,126 protect, and when does it expire?

Patent 12,734,126 protects RYZUMVI and is included in one NDA.

This patent has ten patent family members in eight countries.


Drugs Protected by US Patent 12,734,126

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Famygen Life Sci RYZUMVI phentolamine mesylate SOLUTION;OPHTHALMIC 217064-001 Sep 25, 2023 RX Yes Yes 12,734,126 ⤷  Start Trial A METHOD OF PUPIL REDUCTION ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,734,126

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2014212274 ⤷  Start Trial
Australia 2018200566 ⤷  Start Trial
Canada 2899339 ⤷  Start Trial
Denmark 2950648 ⤷  Start Trial
European Patent Office 2950648 ⤷  Start Trial
Spain 2762153 ⤷  Start Trial
Japan 2016506966 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.